Please login to the form below

Not currently logged in
Email:
Password:

emicizumab

This page shows the latest emicizumab news and features for those working in and with pharma, biotech and healthcare.

Ocrevus surge keeps Roche smiling in Q3

Ocrevus surge keeps Roche smiling in Q3

Another bright spot for Roche was strong early uptake of new haemophilia A therapy Hemlibra (emicizumab), a blockbuster-in-waiting which added CHF 113m to the pot from its use in

Latest news

  • Bayer roll-out of haemophilia drug Jivi gathers pace Bayer roll-out of haemophilia drug Jivi gathers pace

    Meanwhile, the imminent regulatory verdict in the US for Roche’s Hemlibra (emicizumab) in haemophilia A patients without inhibitors to factor VIII, which could dramatically broaden the number of patients eligible

  • Roche highlights Hemlibra data as key FDA date approaches Roche highlights Hemlibra data as key FDA date approaches

    The HAVEN-3 trial – first reported last year and now published in the New England Journal of Medicine – shows that Hemlibra (emicizumab-kxwh) is effective at reducing bleeding episodes in haemophilia

  • Immunology keeps Shire figures solid as Takeda takeover nears Immunology keeps Shire figures solid as Takeda takeover nears

    However, Shire’s drugs for haemophilia patients with inhibitors such as Feiba came under competitive pressure from the likes of Roche’s recently-approved Hemlibra (emicizumab), falling 6%.

  • NHS England says yes to Roche's Hemlibra NHS England says yes to Roche's Hemlibra

    Brigitte Nolet, Rare Diseases Lead at Roche UK said, “We are delighted that NHS England has agreed to reimburse emicizumab, which has been shown in clinical trials to significantly reduce bleeds ... which has ensured access to emicizumab for patients

  • The year of the blockbuster The year of the blockbuster

    Hemlibra (emicizumab) from Roche/Chugai:A novel approach to treating haemophilia A with inhibitors, once-weekly Hemlibra (emicizumab) is a bispecific antibody that simultaneously binds to both factor IXa and factor

More from news
Approximately 5 fully matching, plus 17 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again – in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics